The use of bone morphogenic protein-7 (OP-1) in the management of resistant non-unions in the upper and lower limb

Papanna, Madhavan C.; Al-Hadithy, Nawfal; Somanchi, Brinda Vihari; Sewell, Mathew D.; Robinson, PM; Khan, SA; Wilkes, RA

doi:10.1016/j.injury.2012.03.007

Cited by 35 publications

(16 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bone repair is a complex process of biological events regulated by specific cells, the extracellular matrix, distinct growth factors and a variety of hormones [92][93][94][95][96][97][98][99][100]. Despite the increased intrinsic capacity of bone to restore fracture healing without scar formation, non-union may still occur in 5-10% of the cases [101].…”

Section: Discussionmentioning

confidence: 99%

The role of pleiotrophin in bone repair

Lamprou

Kaspiris

Panagiotopoulos

et al. 2014

Injury

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

The role of pleiotrophin in bone repair

Lamprou

Kaspiris

Panagiotopoulos

et al. 2014

Injury

View full text Add to dashboard Cite

“…Moreover, rhBMPs provided comparable results to ABG treatment [14,48,54] with shorter operative time, reduced operative blood loss, and avoiding donor site morbidity [14,36]. Regarding safety, comparative studies did not show a higher complication rate, with some adverse events reported only in 3 non-comparative papers [40,44,52] describing cases of heterotopic ossification [40,44] or tibiofibular synostosis [52].…”

Section: Discussionmentioning

confidence: 99%

“…On the other hand, this literature research also revealed that most of the clinical findings are based on case reports or case series with small patient populations, characterized by different delivery approaches, anatomical locations, bone pathologies and dosages, which makes it difficult to draw any final conclusion about the real potential of BMPs therapy and the best protocol they can be applied to [43][44][45][46][47][48][49][50][51][52][53][54][55][56][57][58][59]. Therefore, further research in this direction is needed.…”

Section: Discussionmentioning

confidence: 99%

“…The analysis of the comparative studies underlining a higher percentage of complications, showed that the majority of complications after BMPs treatment were related to heterotopic ossification, which were reported in 3 papers on fracture repair [25,29,34], in 2 papers on non union treatment [40,44], and in 1 paper on osteonecrosis [59] involving both rhBMP-2 and 7. Moreover, other described complications were infections [26,55], peripheral oedema, heterotopic ossification/soft-tissues calcification, new or increased pain [26], and the development of distal tibiofibular synostosis (1/52) described with rhBMP-7 for non-union treatment [52].…”

Section: Complicationsmentioning

confidence: 99%

See 1 more Smart Citation

Clinical application of bone morphogenetic proteins for bone healing: a systematic review

Krishnakumar

Roffi

Reale

et al. 2017

International Orthopaedics (SICOT)

View full text Add to dashboard Cite

Purpose This paper documents the existing evidence on bone morphogenetic proteins (BMPs) use for the treatment of bone fractures, non-union, and osteonecrosis, through a review of the clinical literature, underlying potential and limitations in terms of cost effectiveness and risk of complications. Methods A systematic review was performed on the PubMed database using the following string: (bone morphogenetic proteins OR BMPs) and (bone repair OR bone regeneration) including papers from 2000 to 2016. The search focused on clinical trials dealing with BMPs application to favor bone regeneration in bone fractures, non-union, and osteonecrosis, in English language, with level of evidence I, II, III, and IV. Relevant data (type of study, number of patients, BMPs delivery material, dose, site, follow-up, outcome, and adverse events) were extracted and analyzed. Results Forty-four articles met the inclusion criteria: 10 randomized controlled trials (RCTs), 7 comparative studies, 18 case series, and 9 case reports. rhBMP-2 was documented mainly for the treatment of fractures, and rhBMP-7 mainly for non-unions and osteonecrosis. Mixed results were found among RCTs and comparative papers: 11 reported positive results for BMPs augmentation, 3 obtained no significant effects, and 2 showed negative results. The only study comparing the two BMPs showed a better outcome with rhBMP-2 for non-union treatment. Conclusion Clinical evidence on BMPs use for the treatment of fractures, non-union, and osteonecrosis is still controversial, with the few available reports being mainly of low quality. While positive findings have been described in many studies, mixed results are still present in the literature in terms of efficacy and adverse events. The difficulties in drawing clear conclusions are also due to the studies heterogeneity, mainly in terms of different BMPs applied, with different concomitant treatments for each bone pathology. Therefore, further research with well-designed studies is needed in order to understand the real potential of this biological approach to favour bone healing.

show abstract

“…The local delivery of growth factors, such as basic fibroblast growth factor (bFGF), to fracture sites is one of the treatment options for accelerating fracture healing . bFGF is expressed in periosteum during mesenchymal cell proliferation and chondrogenesis, and stimulates the growth of many cell types, including osteoblasts and chrondrocytes .…”

Section: Introductionmentioning

confidence: 99%

Acceleration of bone formation during fracture healing by poly(pro–hyp–gly)₁₀ and basic fibroblast growth factor containing polycystic kidney disease and collagen‐binding domains from Clostridium histolyticum collagenase

Sekiguchi

Uchida

Inoue

et al. 2016

J Biomedical Materials Res

View full text Add to dashboard Cite

Growth factor delivered in combination with animal-derived collagen materials has been used to accelerate bone fracture healing in human patients. However, the introduction of bovine proteins into humans carries the risk of zoonotic and immunologic complications. Here, we developed a collagen-like polypeptide-based bone formation system consisting of poly(Pro-Hyp-Gly)10 , which mimics the triple helical conformation of collagen, and basic fibroblast growth factor (bFGF) fused to the polycystic kidney disease (PKD) domain and collagen-binding domain (CBD) of Clostridium histolyticum collagenase. Circular dichroism spectral analysis showed that when pepsin-soluble bovine type I collagen was treated at 50°C, a positive signal corresponding to the collagen triple helix at 220 nm was not detected. In contrast, poly(Pro-Hyp-Gly)10 retained the 220-nm positive peak, even when treated at 80°C. The combination of the collagen binding-bFGF fusion protein (bFGF-PKD-CBD) with poly(Pro-Hyp-Gly)10 induced greater bone formation compared to bFGF alone in mice bone fracture models. Taken together, these properties suggest that the bFGF-PKD-CBD/poly(Pro-Hyp-Gly)10 composite is a promising material for bone repair in the clinical setting. © 2016 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 104A: 1372-1378, 2016.

show abstract

The use of bone morphogenic protein-7 (OP-1) in the management of resistant non-unions in the upper and lower limb

Cited by 35 publications

References 23 publications

The role of pleiotrophin in bone repair

The role of pleiotrophin in bone repair

Clinical application of bone morphogenetic proteins for bone healing: a systematic review

Acceleration of bone formation during fracture healing by poly(pro–hyp–gly)₁₀ and basic fibroblast growth factor containing polycystic kidney disease and collagen‐binding domains from Clostridium histolyticum collagenase

Contact Info

Product

Resources

About

The use of bone morphogenic protein-7 (OP-1) in the management of resistant non-unions in the upper and lower limb

Cited by 35 publications

References 23 publications

The role of pleiotrophin in bone repair

The role of pleiotrophin in bone repair

Clinical application of bone morphogenetic proteins for bone healing: a systematic review

Acceleration of bone formation during fracture healing by poly(pro–hyp–gly)10 and basic fibroblast growth factor containing polycystic kidney disease and collagen‐binding domains from Clostridium histolyticum collagenase

Contact Info

Product

Resources

About

Acceleration of bone formation during fracture healing by poly(pro–hyp–gly)₁₀ and basic fibroblast growth factor containing polycystic kidney disease and collagen‐binding domains from Clostridium histolyticum collagenase